Zacks: Analysts Anticipate Five Prime Therapeutics Inc (FPRX) Will Post Quarterly Sales of $8.00 Million
Brokerages expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report $8.00 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $4.10 million and the highest is $13.42 million. Five Prime Therapeutics reported sales of $13.22 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 39.5%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 26th.
On average, analysts expect that Five Prime Therapeutics will report full year sales of $52.48 million for the current year, with estimates ranging from $49.94 million to $53.84 million. For the next fiscal year, analysts expect that the firm will post sales of $28.86 million, with estimates ranging from $7.30 million to $60.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $7.45 million.
Five Prime Therapeutics stock opened at $12.90 on Friday. Five Prime Therapeutics has a 1-year low of $10.35 and a 1-year high of $24.82. The company has a market capitalization of $451.12 million, a P/E ratio of -2.40 and a beta of 3.34.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Five Prime Therapeutics by 3.0% during the third quarter. Vanguard Group Inc. now owns 2,251,778 shares of the biotechnology company’s stock worth $31,344,000 after purchasing an additional 66,485 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in Five Prime Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 30,852 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 10,895 shares during the last quarter. Platinum Investment Management Ltd. raised its holdings in Five Prime Therapeutics by 29.1% during the third quarter. Platinum Investment Management Ltd. now owns 121,576 shares of the biotechnology company’s stock worth $1,692,000 after purchasing an additional 27,376 shares during the last quarter. BlueMountain Capital Management LLC raised its holdings in Five Prime Therapeutics by 398.9% during the third quarter. BlueMountain Capital Management LLC now owns 14,766 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 11,806 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in Five Prime Therapeutics during the third quarter worth $1,569,000. 85.99% of the stock is owned by hedge funds and other institutional investors.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Read More: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.